regulatory
confidence high
sentiment negative
materiality 0.70
Outlook Therapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period
Outlook Therapeutics, Inc.
- Received Nasdaq letter on Feb 18, 2026, for closing bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until August 17, 2026, to regain compliance.
- To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
- If not compliant by Aug 17, may be eligible for additional 180-day period if it meets other standards.
- Company will monitor bid price and evaluate options including reverse stock split.